The first GLP-1 RA approved for weight loss in overweight and obesity, liraglutide, received authorization in the United States (US) market in 2014 [16], and since 2022, 2 GLP-1 RAs (liraglutide, semaglutide) have also been approved for weight loss in European countries [14]. The gene discussed is GCG; the disease is Obesity.